18F-fluorodeoxyglucose positron emission tomography/computer tomography as an objective tool for assessing disease activity in Sjögren's syndrome

Autoimmunity Reviews

Volumn 12, Issue 11, 2013, Pages 1109-1114

  Cohen, Camille ^a   Mekinian, Arsène ^a,b   Uzunhan, Yurdagul ^b,c   Fauchais, Anne Laure ^d   Dhote, Robin ^b,c   Pop, Gabriel ^c   Eder, Véronique ^b,c   Nunes, Hilario ^b,c   Brillet, Pierre Yves ^b,c   Valeyre, Dominique ^b,c   Fain, Olivier ^a,b   Soussan, Michaël ^b,c  

^a HÔPITAL JEAN VERDIER   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c AVICENNE HOSPITAL   (France)

^d LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; FLUORODEOXYGLUCOSE F 18; IMMUNOGLOBULIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED EMISSION TOMOGRAPHY SCANNER; CRYOGLOBULINEMIA; DISEASE ACTIVITY; DRUG UPTAKE; EULAR SJOGREN SYNDROME DISEASE ACTIVITY INDEX SCORE; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG; LYMPH NODE; LYMPHADENOPATHY; LYMPHOMA; MALE; PAROTID GLAND; RADIOGRAPHY DEVICE; SCORING SYSTEM; SJOEGREN SYNDROME; SUBMANDIBULAR GLAND; THYROID GLAND;

AGED; AMINO ACYL-TRNA SYNTHETASES; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SJOGREN'S SYNDROME; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84881543287     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.06.012     Document Type: Article

References (29)

1. Castro I., Sepulveda D., Cortes J., Quest A.F., Barrera M.J., Bahamondes V., et al. Oral dryness in Sjogren's syndrome patients. Not just a question of water. Autoimmun Rev 2013, 12(5):567-574.
2. Guellec D., Cornec D., Jousse-Joulin S., Marhadour T., Marcorelles P., Pers J.O., et al. Diagnostic value of labial minor salivary gland biopsy for Sjogren's syndrome: a systematic review. Autoimmun Rev 2013, 12(3):416-420.
3. Garcia-Carrasco M., Ramos-Casals M., Rosas J., Pallares L., Calvo-Alen J., Cervera R., et al. Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore) 2002, 81(4):270-280.
4. Ioannidis J.P., Vassiliou V.A., Moutsopoulos H.M. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum 2002, 46(3):741-747.
5. Seror R., Ravaud P., Bowman S.J., Baron G., Tzioufas A., Theander E., et al. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 2009, 69(6):1103-1109.
6. Lee K.H., Cho A., Choi Y.J., Lee S.W., Ha Y.J., Jung S.J., et al. The role of (18) F-fluorodeoxyglucose-positron emission tomography in the assessment of disease activity in patients with takayasu arteritis. Arthritis Rheum 2011, 64(3):866-875.
7. Soussan M., Augier A., Brillet P.Y., Weinmann P., Valeyre D. Functional imaging in extrapulmonary sarcoidosis: FDG-PET/CT and MR features. Clin Nucl Med 2013, [in press]. 10.1097/RLU.0b013e318279f264.
8. Treglia G., Taralli S., Giordano A. Emerging role of whole-body 18F-fluorodeoxyglucose positron emission tomography as a marker of disease activity in patients with sarcoidosis: a systematic review. Sarcoidosis Vasc Diffuse Lung Dis 2011, 28(2):87-94.
9. Mariette X. Gougerot-Sjögren syndrome. Risk of lymphoma. Presse Med 1999, 28(22):1214-1218.
10. Voulgarelis M., Ziakas P.D., Papageorgiou A., Baimpa E., Tzioufas A.G., Moutsopoulos H.M. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjogren syndrome. Medicine (Baltimore) 2011, 91(1):1-9.
11. Curiel R., Akin E.A., Beaulieu G., DePalma L., Hashefi M. PET/CT imaging in systemic lupus erythematosus. Ann N Y Acad Sci 2011, 1228:71-80.
12. Nowak M., Carrasquillo J.A., Yarboro C.H., Bacharach S.L., Whatley M., Valencia X., et al. A pilot study of the use of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography to assess the distribution of activated lymphocytes in patients with systemic lupus erythematosus. Arthritis Rheum 2004, 50(4):1233-1238.
13. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Med Assoc 2000, 284(23):3043-3045.
14. Baimpa E., Dahabreh I.J., Voulgarelis M., Moutsopoulos H.M. Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 2009, 88(5):284-293.
15. Jonsson M.V., Theander E., Jonsson R. Predictors for the development of non-Hodgkin lymphoma in primary Sjogren's syndrome. Presse Med 2012, 41(9 Pt 2):e511-e516.
16. Zintzaras E., Voulgarelis M., Moutsopoulos H.M. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005, 165(20):2337-2344.
17. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61(6):554-558.
18. Vitali C., Bombardieri S., Moutsopoulos H.M., Coll J., Gerli R., Hatron P.Y., et al. Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis 1996, 55(2):116-121.
19. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002, 165(2):277-304.
20. Fauchais A.L., Monteil J., Gondran G., Manea P., Bezanahary H., Loustaud-Ratti V., et al. TEP-scan et syndrome de Goujerot-Sjögren primitf. La Revue de Médecine Interne 2009, 30:S86.
21. Jadvar H., Bonyadlou S., Iagaru A., Colletti P.M. FDG PET-CT demonstration of Sjögren's sialoadenitis. Clin Nucl Med 2005, 30(10):698-699.
22. Cruz-Tapias P., Rojas-Villarraga A., Maier-Moore S., Anaya J.M. HLA and Sjogren's syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev 2012, 11(4):281-287.
23. Jimenez S.A., Piera-Velazquez S. Potential role of human-specific genes, human-specific microRNAs and human-specific non-coding regulatory RNAs in the pathogenesis of systemic sclerosis and Sjogren's syndrome. Autoimmun Rev 2013, 12(11):1046-1051.
24. Yao Y., Liu Z., Jallal B., Shen N., Ronnblom L. Type I interferons in Sjogren's syndrome. Autoimmun Rev 2013, 12(5):558-566.
25. Ramage A.E., Fox P.T., Brey R.L., Narayana S., Cykowski M.D., Naqibuddin M., et al. Neuroimaging evidence of white matter inflammation in newly diagnosed systemic lupus erythematosus. Arthritis Rheum 2011, 63(10):3048-3057.
26. De La Torre JR Infante, Duran Barquero C., Garcia Bernardo L., Groiss J., Rayo Madrid J.I., Serrano Vicente J., et al. Coexistence of two different types of lymphoma in a patient with Sjogren's syndrome. The usefulness of the PET-CT. Rev Esp Med Nucl Imagen Mol 2011, 31(1):28-30.
27. Watanabe Y., Koyama S., Miwa C., Okuda S., Kanai Y., Tetsuka K., et al. Pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma in Sjögren's syndrome showing only the LIP pattern radiologically. Intern Med 2012, 51(5):491-495.
28. Bae Y.A., Lee K.S., Han J., Ko Y.H., Kim B.T., Chung M.J., et al. Marginal zone B-cell lymphoma of bronchus-associated lymphoid tissue: imaging findings in 21 patients. Chest 2008, 133(2):433-440.
29. Ghillani P., Andre C., Toly C., Rouquette A.M., Bengoufa D., Nicaise P., et al. Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study. Autoimmun Rev 2011, 10(9):509-513.